Journal
CANCER LETTERS
Volume 469, Issue -, Pages 111-123Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2019.10.026
Keywords
Ewing sarcoma; Noncoding RNA; HULC; TWIST1
Categories
Funding
- Associazione Italiana Ricerca sul Cancro (AIRC) [IG21877]
- Sarcoma Foundation of America [SFA 582104]
- Fondazione Umberto Veronesi
Ask authors/readers for more resources
Ewing sarcomas (ES) are aggressive pediatric cancers of bone and soft tissues characterized by in frame chromosomal translocations giving rise to chimeric transcription factors, such as EWS-FLI1. An emerging strategy to block EWS-FLI1 activity is represented by the small molecule YK-4-279, which binds to EWS-FLI1 and alters its transcriptional activity. The specific effectors of the anti-oncogenic activity of YK-4-279 are still largely unknown. Herein, by performing a high-throughput screening we identify the IncRNA HULC (Highly Upregulated in Liver Cancer) as a prominent target of YK-4-279 activity in ES cells. High levels of HULC correlate with ES aggressiveness, whereas HULC depletion reduces ES cell growth. Mechanistically, we find that HULC promotes the expression of TWIST1 oncogene by sponging miR-186. Downregulation of HULC upon treatment with YK-4279 reduces the expression of TWIST1 by unleashing miR-186 and favoring its binding to TWIST1 transcripts. Notably, high levels of miR-186 and low levels of TWIST1 correlate with better prognosis in ES patients. Our results disclose a novel oncogenic regulatory circuit mediated by HULC IncRNA that is disrupted by the small molecule YK-4-279, with promising therapeutic implications for ES treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available